Aim: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma.
Materials & Methods: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation.
Results: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years.
Conclusion: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon.16.2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of CPAP on Central and Peripheral Blood Pressure in Patients with Uncontrolled Hypertension and OSA: The MORPHEOS Trial.
Ann Am Thorac Soc
January 2025
Heart Institute (InCor) University of São Paulo Medical School, Brazil, Hypertension Unit, São Paulo, Brazil.
Rationale: Previous studies evaluating the effect of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) on blood pressure (BP) showed variable results. Moreover, several studies recruited patients with normal or controlled BP, and compliance to antihypertensive drugs was not monitored. In addition, very few studies investigated central BP in this scenario.
View Article and Find Full Text PDFFavourable Living Donor Kidney Transplantation Outcomes within a National Kidney Exchange Program: A Propensity Score Matching Analysis.
Clin J Am Soc Nephrol
January 2025
Erasmus MC Transplant Institute, Department of Surgery, Division of HPB & Transplant Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Background: KEPs (kidney exchange programs) facilitate living donor kidney transplantations (LDKT) for patients with incompatible donors, who are typically higher risk than non-KEP patients because of higher sensitization and longer dialysis vintage. We conducted a comparative analysis of graft outcomes and risk factors for both KEP and non-KEP living donor kidney transplants.
Methods: All LDKTs performed in the Netherlands between 2004-2021 were included.
Tackling chronic kidney disease in Nepal: from evidence to action.
J Nephrol
January 2025
Health Evidence Synthesis, Recommendations and Impact (HESRI), School of Public Health, The University of Adelaide, Adelaide, South Australia, Australia.
Chronic kidney disease (CKD) poses a significant burden in Nepal. We reviewed the epidemiology of CKD in Nepal and proposed strategies to mitigate its burden. A nationwide survey of non-communicable diseases in 2019 reported CKD prevalence of 6.
View Article and Find Full Text PDF[A rapid review: quality of life in adult allogeneic kidney transplantation in the last five years : What can we learn?].
Urologie
January 2025
Universitätsklinik für Urologie, Universität Bern, Inselspital Bern, Bern, Schweiz.
Background: Recent studies have also shown that clinical monitoring of quality of life (HRQoL) helps to recognize kidney transplant failure at an early stage.
Objectives: Given the potential of improving HRQoL for the long-term outcomes of kidney transplantation, we conducted a rapid review of the last 5 years of quality of life evaluation after adult allogeneic kidney transplantation.
Materials And Methods: A rapid evidence analysis was carried out using a literature search in MEDLINE in the period 2019-2024.
Tranexamic dosing for major joint arthroplasty in adult patients with chronic kidney disease: A pharmacokinetic study and new dosing regimen.
Anesthesiology
January 2025
Department of Anesthesiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Background: Tranexamic acid is an anti-fibrinolytic agent routinely used during hip and knee joint replacement surgery to minimize bleeding. Chronic kidney disease is a common chronic health problem seen among adults requiring major arthroplasty surgery. Tranexamic acid is renally cleared and may accumulate in chronic kidney disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!